Low Seroconversion with Hepatitis B Vaccination in Peritoneal Dialysis Patients

1996 ◽  
Vol 16 (4) ◽  
pp. 370-373 ◽  
Author(s):  
Abdul N. Khan ◽  
Judy Bernardini ◽  
Raymond M. Rault ◽  
Beth Piraino

Objective To compare seroconversion using hepatitis B vaccine between hemodialysis (HD) and peritoneal dialysis (PD) patients. Design Data on PD patients vaccinated were collected retrospectively for the period 1992 to 1995. The data on HD patients were collected prospectively from 1991 to 1994. Setting A university outpatient dialysis center. Participants All adult patients who received all four doses of hepatitis B vaccine while on dialysis were included (47 PD and 50 HD patients). Intervention Recombinant hepatitis B vaccine (Engerix), 40 μg IM was administered at 0, 1, 2, and 6 months. Main Outcome Measure Seroconversion was measured after completion of the vaccination series. Results 74% of the HD patients seroconverted compared to 53 % of PD patients (p = 0.03). Older, heavier patients compared to all the other patients had a lower seroconversion rate in both the HD patients (55 % vs. 78 %) and PD patients (38 % vs. 59 %) (p = 0.03). Conclusion The seroconversion rate to recombinant hepatitis B vaccine is lower in patients on PD than on HD for unclear reasons. Further studies are required to determine the etiology of this difference.

2003 ◽  
Vol 98 (8) ◽  
pp. 1101-1107 ◽  
Author(s):  
José Luís da S Baldy ◽  
Maria do Carmo M Elisbão ◽  
Edson T Anzai ◽  
Rubens Pontello ◽  
Edna Maria V Reiche ◽  
...  

1991 ◽  
Vol 22 (3) ◽  
pp. 251-257 ◽  
Author(s):  
S.J. Fleming ◽  
D.M. Moran ◽  
W.G.E. Cooksley ◽  
J.L. Faoagali

Vaccine ◽  
2014 ◽  
Vol 32 (48) ◽  
pp. 6521-6526 ◽  
Author(s):  
Christopher L. Gilbert ◽  
Jon E. Stek ◽  
Giuseppe Villa ◽  
Stephanie O. Klopfer ◽  
Jason C. Martin ◽  
...  

2002 ◽  
Vol 23 (2) ◽  
pp. 87-90 ◽  
Author(s):  
E. Geoffrey Playford ◽  
Patrick G. Hogan ◽  
Amolak S. Bansal ◽  
Kareena Harrison ◽  
David Drummond ◽  
...  

Objective:To study the humoral immune responses, safety, and tolerability of intradermal recombinant hepatitis B vaccination in healthcare workers (HCWs) nonresponsive to previous repeated intramuscular vaccination.Design:An open, prospective, before–after trial.Setting:A tertiary referral hospital and surrounding district health service in Queensland, Australia.Participants:Hospital and community HCWs nonresponsive to previous intramuscular hepatitis B vaccination.Methods:Intradermal recombinant hepatitis B vaccine was administered every second week for a maximum of 4 doses. Hepatitis B surface antibody (anti-HBs) responses were assessed 2 weeks after each dose.Results:Protective anti-HBs levels developed in 17 (94%) of 18 study subjects. Three doses resulted in seroconversion of all responding subjects and the highest geometric mean antibody concentration. The vaccine was well tolerated.Conclusion:More than 90% of previously nonresponsive HCWs responded to intradermal recombinant hepatitis B vaccine with protective anti-HBs levels.


Sign in / Sign up

Export Citation Format

Share Document